Over the past few months we have started to deepen our collaboration with the AHSN – Innovation Agency to ensure we are continuously building a proposition that ultimately meets the health demands of the wider population within the United Kingdom. 

There is no hiding that Musculoskeletal (MSK) problems cost the NHS over £7bn annually with over 31 million working days lost. It is therefore important for us to not only build new products but constantly challenge the health status quo and enable people to take control of their recovery.

It’s easy for us to lose sight of the multiple patient groups and their demographics, therefore conducting studies and reviews together with the AHSN is important in ensuring that we are on the right pathway. 

We have continued to work closely with a fantastic team at the Innovation Agency which includes Debbie Parkinson, Andy Cairns and David Dewhurst. This includes receiving feedback from the Patient Safety Ambassadors and the Public Involvement & Engagement Senate (PIES).

Over the next few months we hope to build a strong case for clinical studies to evaluate patient outcomes following the use of our technology. By deepening these ties, this will enable us to drive rapid value to the public health system´s physiotherapy related challenges.

The support has been delivered as part of the LCR Health Matters programme which is part-funded by the European Regional Development Fund

About the AHSN Network

The AHSN Network is the collective voice of the 15 local Academic Health Science Networks. AHSNs operate simultaneously as a single AHSN Network and as fifteen locally embedded and integrated organisations with strong partnerships at place and Integrated Care System level. Their strength comes from the ability to work at local, regional and national levels, and the interplay between them.

The AHSN Network exists to transform the way the NHS identifies, adopts and spreads innovation and is driven by three imperatives: improving health; improving productivity; and generating economic growth.

This is achieved by accelerating access to innovation, transforming patient experience and health outcomes, driving down the cost of care, supporting safer systems of care, and enabling economic growth through AHSNs’ unique support for the life sciences sector.